Plain-English translation of NCT05080556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to giving , a chemotherapy drug commonly used to treat ovarian cancer. Instead of giving everyone the same dose every three weeks, this study will test whether adjusting the dose based on your CA125 blood marker (which measures how much cancer is in your body) works better. The hope is that this personalized approach could help the chemotherapy work longer while also reducing side effects.
Ovarian cancer often comes back after initial treatment, and patients need more chemotherapy. However, standard chemotherapy can cause serious side effects and cancer can become resistant to it over time. This trial is testing whether tailoring the medication dose to each patient's individual response could help extend how long the treatment stays effective while causing fewer side effects.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either standard chemotherapy doses or doses adjusted based on your CA125 blood levels. You will receive chemotherapy and have blood tests before each treatment, during regular check-in visits every 6 weeks, and at follow-up appointments. The trial involves providing extra research blood samples alongside your routine blood work, and you will need to be able to start treatment within 4 weeks of enrolling.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United Kingdom